Literature DB >> 10355791

Non-participation bias in unlinked anonymous HIV-prevalence surveys in England and Wales.

T Duong1, A E Ades, P Rogers, A Nicoll.   

Abstract

The objective was to assess the potential bias in unlinked anonymous HIV-seroprevalence surveys from objections to specimens being included. Objection rates in seroprevalence surveys were examined. Statistically large clusters of objections were considered to be the result of health care worker behaviour, and were disregarded. Underlying objection rates were estimated from remaining data and compared to seroprevalence. Overall objection rates approached or exceeded seroprevalence in many participating centres. However, underlying objection rates declined with time while prevalences were generally unchanging. Also, underlying rates correlated poorly with observed seroprevalences. Findings were therefore consistent with processes producing the clusters of objections and underlying objection rates independently of serostatus of individuals. Although national seroprevalence estimates produced by the surveys are reasonably free from objection bias, regional seroprevalence estimates outside London remain vulnerable to bias as a result of some centres returning data whose quality cannot be guaranteed.

Entities:  

Mesh:

Year:  1999        PMID: 10355791      PMCID: PMC2809615          DOI: 10.1017/s0950268899002095

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  2 in total

1.  Trends in undiagnosed HIV-1 infection among attenders at genitourinary medicine clinics, England, Wales, and Northern Ireland: 1990-6.

Authors:  I Simms; P Rogers; M Catchpole; C A McGarrigle; A Nicoll
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

2.  The ethics of unlinked anonymous testing of blood: views from in-depth interviews with key informants in four countries.

Authors:  Anthony S Kessel; Jessica Datta; Kaye Wellings; Sarah Perman
Journal:  BMJ Open       Date:  2012-12-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.